Introduction: A Nuclear Vision for Viksit Bharat@2047 As India marches toward its ambitious goal of becoming a developed nation by 2047, energy security stands as a pivotal pillar in the vision of Viksit Bharat . Amid the global climate crisis and rising energy demands, nuclear power has re-emerged as a compelling solution. India’s commitment to achieving 100 GW of nuclear power capacity by 2047 is both visionary and necessary—but achieving this requires a strategic shift in policy, participation, and international cooperation. While India’s nuclear energy sector has traditionally been a tightly controlled domain under government monopoly—primarily led by the Department of Atomic Energy (DAE) and Nuclear Power Corporation of India Limited (NPCIL) —it is now imperative to welcome private sector investments and foreign partnerships. A reformed nuclear ecosystem can unlock the full potential of atomic energy as a clean, reliable, and scalable contributor to India’s net-zero aspiration...
Hemophilia A, a hereditary bleeding disorder caused by the deficiency of clotting Factor VIII, has long been a challenge for the medical community. With patients often requiring lifelong injections of clotting factors, treatment remains both costly and inconvenient. However, Indian scientists have recently achieved a groundbreaking milestone by successfully testing a gene therapy technique aimed at curing severe Hemophilia A. This innovative approach promises a one-time treatment that could revolutionize the lives of thousands of patients worldwide. Understanding Hemophilia A Hemophilia A is a genetic disorder characterized by the deficiency or malfunction of Factor VIII, an essential protein involved in blood clotting. Patients with severe hemophilia have less than 1% of the normal clotting factor levels, making them prone to spontaneous and potentially life-threatening bleeding episodes. Global and National Impact India has the second-largest hemophilia patient pool globally, with e...